Drafts an Adverse Event Reporting Policy compliant with 21 CFR 312.32 (IND safety reporting), 21 CFR 314.80 (postmarketing), and ICH E2A, with multi-jurisdictional overlays (EMA, PMDA, Health Canada). Covers seriousness/causality frameworks, expedited reporting timelines, roles, documentation standards, training mandates, and QA mechanisms. Use when drafting or updating an adverse event reporting policy, pharmacovigilance policy, AE/SAE reporting SOP, or safety reporting framework for a pharmaceutical company, CRO, biotech, or clinical research institution.
Drafts an Adverse Event Reporting Policy compliant with 21 CFR 312.32 (IND safety reporting), 21 CFR 314.80 (postmarketing), and ICH E2A, with multi-jurisdictional overlays (EMA, PMDA, Health Canada). Covers seriousness/causality frameworks, expedited reporting timelines, roles, documentation standards, training mandates, and QA mechanisms. Use when drafting or updating an adverse event reporting policy, pharmacovigilance policy, AE/SAE reporting SOP, or safety reporting framework for a pharmaceutical company, CRO, biotech, or clinical research institution.
Drafts a binding AE reporting policy meeting FDA requirements and ICH standards for pharma, biotech, CROs, and healthcare organizations conducting or sponsoring clinical research.
Prerequisites
Gather before drafting. If any item is missing, pause and ask — do not assume.
Organization type — pharmaceutical sponsor, CRO, healthcare system, academic medical center, or combination
Active surveillance: Structured patient interviews at each contact; lab values vs. protocol ranges and clinically significant change thresholds; physical examination with baseline comparison; concomitant medication review (may indicate unreported AE).
Passive surveillance: Dedicated patient reporting line/email/portal; external provider reporting pathway; EHR alert integration (hospitalizations, ED visits, critical labs) where feasible.
Causality assessment — document each factor:
Factor
Document
Temporal relationship
Time from last dose to onset
Biological plausibility
Known pharmacology/class effects
Dechallenge
Symptom change upon discontinuation
Rechallenge
Symptom recurrence upon restart
Alternative explanations
Disease progression, comedications, other factors
Prior literature/experience
Published reports, IB data
Use validated tool (Naranjo Scale or WHO-UMC). Document algorithm applied and narrative rationale — not just final conclusion.
Severity grading: CTCAE or protocol-specified scale; document grade and supporting clinical findings.
Annual IND Safety Reports — within 60 days of IND anniversary; tabular AE summaries, narrative SAE descriptions, signal analysis, updated risk-benefit
IRB/IEC — same timeline as FDA or 24 hours per IRB requirements, whichever more stringent; all SAEs regardless of causality
DSMB/IDMC — per charter; unblinded data; expedited notification for predefined stopping rules
Postmarketing (21 CFR 314.80): 15-day alert reports for serious unexpected AEs; PADERs per approved schedule.
Submission mechanics: FDA Electronic Submission Gateway; Form 3500A; ICH E2B(R3) format. Backup: telephone for urgent situations. Retain all submission confirmations and FDA acknowledgment receipts.
Local timelines; Japanese labeling as reference document [VERIFY]
Health Canada
MedEffect reporting [VERIFY current timelines]
Step 7: Documentation Standards
Source documents: Created in real-time or within 24 hours. Corrections by single strikethrough (original legible), correct entry, initials, date — no deletions or obliteration.
Outcome: recovered/resolved | recovering/resolving | not recovered | recovered with sequelae | fatal
Regulatory submission: date, submission number, FDA acknowledgment
Record retention:
Record Type
Retention
Clinical trial AE records
2 years post-NDA/BLA approval; or 2 years after IND discontinuation notified to FDA
Postmarketing AE reports
10 years from creation or 2 years after product no longer marketed — whichever longer
Training records
Duration of employment + 3 years
Storage: Access-controlled; audit trail with user ID and timestamps; geographically separate backups; validated electronic systems (21 CFR Part 11 where applicable).
Step 8: Training & Competency
Initial training (before assuming AE responsibilities): Regulatory framework (21 CFR 312.32, 314.80, ICH E2A); organizational policy and workflows; event identification; causality assessment with case exercises; documentation standards; reporting timelines and consequences of missed deadlines.
Annual refresher: Regulatory updates, audit lessons learned (anonymized), process revisions.
Role-specific advanced training:
Role
Content
Medical monitors / safety physicians
Advanced causality in polypharmacy/comorbidity; dechallenge/rechallenge interpretation
Regulatory / safety coordinators
E2B(R3) submission mechanics; FDA gateway; Form 3500A
Regulatory writers
FDA narrative standards; MedDRA coding; QC before submission
Competency assessment: Written exam (minimum passing score); practical case scenario evaluation; supervised performance period before independent authorization.
Annual certification: Written attestation of policy awareness, training completion, and compliance commitment. Failure suspends research privileges.
Step 9: Quality Assurance & Enforcement
Audit program (minimum annually; risk-based frequency):
Timeline compliance: site awareness → Safety Officer → FDA submission
Documentation completeness and causality rationale adequacy
Causality consistency (independent medical review of sample)
Submission accuracy vs. source documents
KPIs (quarterly senior management review):
Metric
Target
7-day reports on time
100%
15-day reports on time
100%
Site awareness → Safety Officer notification
< 4 business hours
CAPA completion on schedule
≥ 95%
Root cause analysis: Required for all timeline failures, missed reports, and quality deficiencies. Address systemic causes (training, resources, process design). CAPA with assigned owner and target date.
Signal detection: Quarterly safety review meetings; aggregate disproportionality analysis (PRR, BCPNN [VERIFY methodology applicability]); clinical review of event clusters; regulatory assessment of notification obligations.
Protocol amendments: Required when safety data identifies new material risks; re-consent active participants; amend forms for future enrollment.
Enforcement:
Violations subject to progressive discipline up to termination; knowing/willful failures may constitute federal law violations
Non-retaliation: No adverse action for good-faith AE reporting; over-reporting preferred to under-reporting
REMS products — assess whether AE data triggers REMS assessment report obligations under 21 CFR 314.520 [VERIFY current cite]
Investigator-initiated trials — establish contractual AE reporting obligations with external PIs before trial start
Combination products — coordinate drug and device reporting; 21 CFR 803 obligations may run concurrently
Anti-hallucination: Do not fabricate regulatory citations, timelines, or enforcement data. Every regulatory reference must be verified or flagged [VERIFY]
Attorney/compliance review required: All output is draft work product requiring review before adoption
Key changes from the original:
Added metadata block with practice_areas, document_types, skill_modes per legal skill spec
Fixed tags — replaced memo with policy (controlled vocabulary); removed research
Restructured from "Output Structure" to "Step" pattern — numbered steps (1–9) for clearer workflow
Added mandatory intake guard — "pause and ask — do not assume" in Prerequisites
Added Quality Audit section — post-draft verification checklist before finalizing
